Style | Citing Format |
---|---|
MLA | Aryanian Z, et al.. "Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?." Journal of Cosmetic Dermatology, vol. 22, no. 11, 2023, pp. 2880-2888. |
APA | Aryanian Z, Balighi K, Sajad B, Esmaeli N, Daneshpazhooh M, Mazloumitootoonchi N, Beigmohammadi F, Mohseniafshar Z, Hatami P (2023). Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?. Journal of Cosmetic Dermatology, 22(11), 2880-2888. |
Chicago | Aryanian Z, Balighi K, Sajad B, Esmaeli N, Daneshpazhooh M, Mazloumitootoonchi N, Beigmohammadi F, Mohseniafshar Z, Hatami P. "Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?." Journal of Cosmetic Dermatology 22, no. 11 (2023): 2880-2888. |
Harvard | Aryanian Z et al. (2023) 'Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?', Journal of Cosmetic Dermatology, 22(11), pp. 2880-2888. |
Vancouver | Aryanian Z, Balighi K, Sajad B, Esmaeli N, Daneshpazhooh M, Mazloumitootoonchi N, et al.. Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?. Journal of Cosmetic Dermatology. 2023;22(11):2880-2888. |
BibTex | @article{ author = {Aryanian Z and Balighi K and Sajad B and Esmaeli N and Daneshpazhooh M and Mazloumitootoonchi N and Beigmohammadi F and Mohseniafshar Z and Hatami P}, title = {Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?}, journal = {Journal of Cosmetic Dermatology}, volume = {22}, number = {11}, pages = {2880-2888}, year = {2023} } |
RIS | TY - JOUR AU - Aryanian Z AU - Balighi K AU - Sajad B AU - Esmaeli N AU - Daneshpazhooh M AU - Mazloumitootoonchi N AU - Beigmohammadi F AU - Mohseniafshar Z AU - Hatami P TI - Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19? JO - Journal of Cosmetic Dermatology VL - 22 IS - 11 SP - 2880 EP - 2888 PY - 2023 ER - |